These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30181581)

  • 1. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
    Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
    Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 3. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
    Dholaria BR; Bachmeier CA; Locke F
    BioDrugs; 2019 Feb; 33(1):45-60. PubMed ID: 30560413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.
    Othman T; Logan AC; Muffly L; Leonard J; Park J; Shah B; Aldoss I
    J Natl Compr Canc Netw; 2024 Oct; 22(8):. PubMed ID: 39413830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
    Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG
    J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical care management of chimeric antigen receptor T-cell therapy recipients.
    Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
    CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
    Tan AP
    Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
    Foster MC; Savoldo B; Lau W; Rubinos C; Grover N; Armistead P; Coghill J; Hagan RS; Morrison K; Buchanan FB; Cheng C; Laing S; Ivanova A; West J; Foster A; Serody J; Dotti G
    Blood; 2021 Jun; 137(23):3306-3309. PubMed ID: 33624095
    [No Abstract]   [Full Text] [Related]  

  • 18. Neurological Complications of CAR T Cell Therapy.
    Landry K; Thomas AA
    Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
    Ceppi F; Gardner RA
    Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicities of CD19 CAR-T cell immunotherapy.
    Hirayama AV; Turtle CJ
    Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.